natgillin/translations-raw huggingface dataset:
Graden af variation mellem individuelle patienter og laboratorieanalyser af CD34+ celler betyder, at en direkte sammenligning af forskellige studier er vanskelig.
The degree of variation between individual patients and between laboratory assays of CD34+ cells mean that direct comparison between different studies is difficult.
Graden og hyppigheden af hyperglykæmi, som blev observeret i de to pivotalstudier hos akromegalipatienter, var højere ved behandling med Signifor til intramuskulær anvendelse end med den aktive kontrol (octreotid i.m. eller lanreotid som dyb s.c.-injektion).
The degree and frequency of hyperglycaemia observed in the two pivotal studies in acromegaly patients were higher with Signifor intramuscular use than with active control (octreotide intramuscular use or lanreotide deep subcutaneous injection).
Graden og tidsforløbet af serokonversion var sammenlignelig hos patienter med tidligere eksponering for toksin A og toksin A-naive patienter og mellem toksin A-resistente og toksin A- responderende patienter.
The extent and time course of seroconversion were similar in patients with prior toxin A exposure and those who were toxin A naïve, and between toxin A resistant and toxin A responsive patients.
grader, der ikke er
not assessed)
Graderne følger CTCAE version 3.0.
The grades follow CTCAE Version 3.0.
Gradvis dosisforøgelse af ritonavir i behandlingens begyndelse kan medvirke til at øge tolerancen.Behandling bør indledes med 300 mg (3 breve) to gange daglig i en periode på 3 dage og øges gradvist med 100 mg (1brev) to gange daglig op til 600 mg to gange daglig over en periode på højst 14 dage.
Treatment should be initiated at 300 mg (three sachets) twice daily for a period of three days and increased by 100 mg (one sachet) twice daily increments up to 600 mg twice daily over a period of no longer than 14 days.
Gradvis dosisforøgelse af ritonavir i behandlingens begyndelse kan medvirke til at øge tolerancen.Behandling bør indledes med 300 mg (3 tabletter) to gange daglig i en periode på 3 dage og øges gradvist med 100 mg (1 tablet) to gange daglig op til 600 mg to gange daglig over en periode på højst 14 dage.
Treatment should be initiated at 300 mg (3 tablets) twice daily for a period of three days and increased by 100 mg (1 tablet) twice daily increments up to 600 mg twice daily over a period of no longer than 14 days.
Gradvis dosisforøgelse af ritonavir i behandlingens begyndelse kan medvirke til at øge tolerancen.Behandling bør indledes med 300 mg (3,75 ml) to gange daglig i en periode på 3 dage og øges gradvist med 100 mg (1,25 ml) to gange daglig op til 600 mg to gange daglig over en periode på højst 14 dage.
Treatment should be initiated at 300 mg (3.75 ml) twice daily for a period of three days and increased by 100 mg (1.25 ml) twice daily increments up to 600 mg twice daily over a period of no longer than 14 days.
Gradvis dosisreduktion eller hyppigere dosering synes ikke at hjælpe.
Gradual reduction of dose or frequency does not appear to be beneficial.
Gradvis stigning i doseringen af alfa- blokker kan associeres med yderligere reduktion af blodtryk hos patienter, der får vardenafil.
Stepwise increase in alpha-blocker dose may be associated with further lowering of blood pressure in patients taking vardenafil.
Gradvis stigning i doseringen af alfa-blokker kan associeres med yderligere reduktion af blodtryk hos patienter, der får vardenafil.
Stepwise increase in alpha-blocker dose may be associated with further lowering of blood pressure in patients taking vardenafil.
Gradvis stigning i doseringen af alfa-blokker kan være associeret med yderligere blodtryksreduktion hos patienter, der får vardenafil.
Stepwise increase in alpha-blocker dose may be associated with further lowering of blood pressure in patients taking vardenafil.
Gradvis øgning fra 3 til 10 til 30 mg
Gradual escalation from 3 to 10 to 30 mg
Grad≥3
Grades≥3
Graf over induktionstransplantationsregimer.
Induction Transplant Regimens Graph
Graf over induktionstransplantationsregimer.
Induction Transplant Regimens Graph.
Grafen over induktionstransplantationsregimerne skal indeholde følgende nøgleelementer: instruktioner i ordinering og administration, herunder cyklussernes længde og antal cyklusser, for herved at minimere risikoen for lægmiddel- eller administrationsfejl, der kunne opstå grundet de to forskellige bortezomibkombinationsregimer i transplantationsinduktionsregi (Bortezomib Accord plus dexamethason og Bortezomib Accord plus dexamethason og thalidomid). for at minde patienter, der modtager Bortezomib Accord sammen med thalidomid, om, at de skal overholde det svangerskabsforebyggende program for thalidomid, og med reference til produktresuméet for thalidomid for yderligere oplysninger.
Induction Transplant Regimens Graph shall contain the following key elements: instructions for prescribing and administration including the cycles’ length and number of cycles, to minimise the risk of medication and dispensing errors potentially induced by the existence of the two different bortezomib combination regimens in the Transplant Induction Setting (Bortezomib Accord plus dexamethasone, and Bortezomib Accord plus dexamethasone and thalidomide). to remind that patients receiving Bortezomib Accord in combination with thalidomide should adhere to the pregnancy prevention programme of thalidomide, with reference to the SmPC of thalidomide for additional information.
Grafen over induktionstransplantationsregimerne skal indeholde følgende nøgleelementer: instruktioner i ordinering og administration, herunder cyklussernes længde og antal cyklusser, for herved at minimere risikoen for lægmiddel- eller administrationsfejl, der kunne opstå grundet de to forskellige bortezomibkombinationsregimer i transplantationsinduktionsregi (Bortezomib SUN plus dexamethason og Bortezomib SUN plus dexamethason ogthalidomid). for at minde patienter, der modtager Bortezomib SUN sammen med thalidomid, om, at de skal overholde det svangerskabsforebyggende program for thalidomid, og med reference til produktresuméet for thalidomid for yderligere oplysninger.
Induction Transplant Regimens Graph shall contain the following key elements: instructions for prescribing and administration including the cycles’ length and number of cycles, to minimise the risk of medication and dispensing errors potentially induced by the existence of the two different bortezomib combination regimens in the Transplant Induction Setting (Bortezomib SUN plus dexamethasone, and Bortezomib SUN plus dexamethasone and thalidomide). to remind that patients receiving Bortezomib SUN in combination with thalidomide should adhere to the pregnancy prevention programme of thalidomide, with reference to the SmPC of thalidomide for additional information.
Grafen over induktionstransplantationsregimerne skal indeholde følgende nøgleelementer: instruktioner i ordinering og administration, herunder cyklussernes længde og antal cyklusser, for herved at minimere risikoen for lægmiddel- eller administrationsfejl, der kunne opstå grundet de to forskellige bortezomibkombinationsregimer i transplantationsinduktionsregi (VELCADE plus dexamethason og VELCADE plus dexamethason og thalidomid). for at minde patienter, der modtager VELCADE sammen med thalidomid, om, at de skal overholde det svangerskabsforebyggende program for thalidomid, og med reference til produktresuméet for thalidomid for yderligere oplysninger.
Induction Transplant Regimens Graph shall contain the following key elements: instructions for prescribing and administration including the cycles’ length and number of cycles, to minimise the risk of medication and dispensing errors potentially induced by the existence of the two different bortezomib combination regimens in the Transplant Induction Setting (VELCADE plus dexamethasone, and VELCADE plus dexamethasone and thalidomide). to remind that patients receiving VELCADE in combination with thalidomide should adhere to the pregnancy prevention programme of thalidomide, with reference to the SmPC of thalidomide for additional information.
graft angriber din krop (graft versus host-sygdom) åndedrætsproblemer
the graft attacks your body (graft versus host disease) respiratory complications
Graft versus host- sygdomb
Graft versus Host Diseaseb
Graft versus host-sygdom (GvHD) er også blevet indberettet (se nedenfor).
Graft versus Host Disease (GvHD) has also been reported (see below).
Graft versus host-sygdom (GvHD) er også blevet rapporteret.
Graft versus Host Disease (GvHD) has also been reported.
Graft versus Host-sygdom forekom hos 10 patienter, som derpå fik ganciclovir eller valganciclovir, enten alene eller i kombination med andre lægemidler.
Graft- versus-host disease occurred in 10 patients who were then given ganciclovir or valganciclovir, either alone or in combination with other medicines.
Graft versus host-sygdomb
Graft versus Host Diseaseb
Graft versus vært- sygdomb
Graft versus Host Diseaseb
Graft-tab forekom hos 6 % af basiliximab-behandlede og 10 % af placebo- behandlede patienter efter 6 måneder.
Graft loss occurred in 6% of basiliximab-treated and 10% of placebo-treated patients by 6 months.
Graft-versus-host-sygdom (GvHD) er også blevet rapporteret.
Graft versus Host Disease (GvHD) has also been reported.
Graftinfektion, stafylokokinfektion
Graft infection, Staphylococcal infection
Gram negative anaerober: S ≤ 1 mg/l og R > 1 mg/l
Gram negative anaerobes: S ≤ 1mg/L and R > 1 mg/L
Gram NexoBrid) AUClast i intervallet fra 4.500-9.820 ngh/ml pr. gram NexoBrid.
4500-9820 ngh/ml per gram of NexoBrid.
Gram-negative aerober: Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli* Haemophilus influenzae * Haemophilus parainfluenzae Klebsiella oxytoca Klebsiella pneumoniae* Moraxella catarrhalis* Morganella morganii Proteus mirabilis*
Gram-negative aerobes: Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli* Haemophilus influenzae* Haemophilus parainfluenzae Klebsiella oxytoca Klebsiella pneumoniae* Moraxella catarrhalis* Morganella morganii Proteus mirabilis
Gramnegative aerobe bakterier Citrobacter freundii* Citrobacter koseri Escherichia coli*
Gram-negative Aerobes Citrobacter freundii* Citrobacter koseri Escherichia coli* Klebsiella oxytoca
Gramnegative aerobe Stenotrophomonas maltophilia Legionella spp.
Gram-negative aerobes Stenotrophomonas maltophilia Legionella spp.
Gramnegative organismer
Gram negative organisms
Grampositive aerobe
Gram-positive aerobes
Grampositive aerobe bakterier Enterococcus spp.† Staphylococcus aureus* Staphylococcus epidermidis Staphylococcus haemolyticus Streptococcus agalactiae*
Gram-positive Aerobes Enterococcus spp.† Staphylococcus aureus* Staphylococcus epidermidis Staphylococcus haemolyticus Streptococcus agalactiae
Grampositive mikroorganismer
Gram-positive micro-organisms
Grampositive mikroorganismer
Gram-positive micro-organisms:
Granatieri – 50018 Scandicci (FI) Italien
Granatieri – 50018 Scandicci (FI) Italy
Grand mal-anfald
Grand mal seizure
Grange road Dublin 13 Irland
Grange road Dublin 13 Ireland
Grange Road, Dublin 13 Irland
Grange Road, Dublin 13 Ireland
Granisetron kan påvirkes af direkte naturligt eller kunstigt sollys.
Granisetron may be affected by direct natural or artificial sunlight.
Granisetron metaboliseres hovedsageligt til 7-hydroxygranisetron og 9’N-desmethylgranisetron.
Granisetron is mainly metabolised to 7-hydroxygranisetron and 9’N-desmethylgranisetron.
Granulat
Granules Granules
Granulat
Granules.
Granulat 30 breve
Granules 30 sachets
Granulat i brev 56 breve
Granule in sachet 56 sachets
Granulat i brev Indeholder 14 breve
Granule in sachet Contains 14 sachets
Granulat i brev.
Granule in sachet.
Granulat i pose
Granules in sachet
Granulat i pose.
Granules in sachet
Granulat oprensning: Eli Lilly and Company, Lilly Technology Center Building 130, Indianapolis, Indiana, USA
Granule Recovery: Eli Lilly and Company, Lilly Technology Center Building 130, Indianapolis, Indiana, USA
Granulat til brug i drikkevand til fasaner (400 g pose)
Granules for use in drinking water for pheasants - 400 g sachet
Granulat til brug i drikkevand til kyllinger og kalkuner - 40 g pose
Granules for use in drinking water for chickens and turkeys - 40 g sachet
Granulat til brug i drikkevand til kyllinger og kalkuner - 400 g pose
Granules for use in drinking water for chickens and turkeys - 400 g sachet
Granulat til brug i drikkevand til svin – 160 g pose
Granules for use in drinking water for pigs – 160 g sachet
Granulat til brug i drikkevand til svin – 40 g-pose
Granules for use in drinking water for pigs – 40 g sachet
Granulat til brug i drikkevand til svin – 400 g pose
Granules for use in drinking water for pigs – 400 g sachet
Granulat til oral
Granules for oral
Granulat til oral
suspension Granules for oral
Granulat til oral suspension Gult granulat
Granules for oral suspension Yellow granules
Granulat til oral suspension med banansmag er et hvidt til råhvidt pulver, som kan indeholde gule eller beige til gulbrune partikler i en foliepose til engangsbrug.
The banana flavoured granules for oral suspension is a white to off-white powder that may contain yellow or beige to tan particles in a single-use sachet.
Granulat til oral suspension skal gives til dit barn inden for 30 minutter efter blanding.
Granules for oral suspension should be given to your child within 30 minutes of mixing.
Granulat til oral suspension skal gives til patienten inden for 30 minutter efter blanding.
Granules for oral suspension should be given to the patient within 30 minutes of mixing.
Granulatet er off-white.
The granules are off-white.
Granulatet i brevene skal opslæmmes i et glas vand indeholdende mindst 30 ml (omkring 1/3 af et almindeligt glas).
Take the granules contained in the sachets as a suspension in a glass containing a minimum of 30 ml (approximately one third of a standard glass) of water.
Granulatet indeholder 124 mg (5,4 mmol) natrium og 768 mg saccharose pr. g natriumfenylbutyrat Alle hjælpestoffer er anført under pkt.
For each gram of sodium phenylbutyrate, the granules contain 124 mg (5.4 mmol) of sodium and 768 mg of sucrose.
Granulatet må ikke knuses eller tygges.
The granules should not be crushed or chewed.
Granulatet skal opløses i et glas koldt vand, og vaccinen skal blandes med den dermed fremstillede bufferopløsning.
The granules should be dissolved in a glass of cool water, and the resulting buffer solution should be mixed with the vaccine.
Granulocyt-kolonistimulerende faktor kan fremme væksten af myeloide celler in vitro, og der kan ses lignende effekter på nogle non-myeloide celler in vitro.
Granulocyte-colony stimulating factor can promote growth of myeloid cells in vitro and similar effects may be seen on some non-myeloid cells in vitro.
Granulocyt-kolonistimulerende faktorer kan fremme væksten af myeloide celler in vitro, og sammenlignelige virkninger kan observeres hos nogle ikke-myeloide celler in vitro.
G-CSF can promote growth of myeloid cells in vitro and similar effects may be seen on some non- myeloid cells in vitro.
Granulocyt-makrofagkolonistimulerende faktor (GM-CSF): 250 µg/m2/dag, administreret ved enten subkutan injektion (anbefales kraftigt) eller intravenøs infusion over 2 timer.
Granulocyte macrophage colony-stimulating factor (GM-CSF): 250 μg/m2/day, administered by either subcutaneous injection (strongly recommended) or intravenous infusion over 2 hours.
granulocytopeni
granulocytopaenia
Granulocytopeni
granulocytopenia
Granulocytopenisås oftere hos børn.
Granulocytopenia was more frequently observed in children.
Granulocytter har vist sig at være mere effektive end PBMC’er til mediering af dinutuximab- afhængig cytotoksicitet for neuroblastomceller, og forstærket cellelysis blev observeret med tilføjelse af GM- CSF.
Granulocytes were found to be more effective than PBMCs in mediating dinutuximab dependent cytotoxicity of neuroblastoma cells, with enhanced cell lysis observed with the addition of GM-CSF.
Granulomatose med polyangiitis eller mikroskopisk polyangiitis
Granulomatosis with polyangiitis or microscopic polyangiitis
Granulomatøs læ sion.
Granulomatous lesion.
GRANUPAS bør ikke anvendes ved stærkt nedsat nyrefunktion.
Patients with severe renal impairment should not receive GRANUPAS.
GRANUPAS forventes ikke at påvirke din evne til at føre motorkøretøj eller betjene maskiner.
GRANUPAS is unlikely to affect your ability to drive and use machines.
GRANUPAS, 4g
GRANUPAS 4g
GRANUPAS, enterogranulat, 4 g Para-aminosalicylsyre
GRANUPAS 4 g gastro-resistant granules Para-aminosalicylic acid
GRANUPAS, enterogranulat, 4g Para-aminosalicylsyre
GRANUPAS 4g gastro-resistant granules Para aminosalicylic acid
Grapefrugt og grapefrugtjuice kan øge koncentrationen af Torisel i blodet og bør undgås.
Grapefruit and grapefruit juice may increase blood concentrations of Torisel and should be avoided.
Grapefrugtjuice
dihydroergotamine,
Grapefrugtjuice kan påvirke virkningen af Tadalafil Mylan og bør indtages med forsigtighed.
Grapefruit juice may affect how well Tadalafil Mylan will work and should be taken with caution.
grapefrugtjuice potente CYP3A4-induktorer såsom rifampicin, phenobarbital, carbamazepin, phenytoin, perikon.
grapefruit juice, potent CYP3A4 inducers including rifampicin, phenobarbital, carbamazepine, phenytoin, St John’s Wort.
Grapefrugtjuice påvirker CYP3A4-medieret metabolisering, og bør derfor undgås.
Grapefruit juice affects CYP3A4-mediated metabolism, and should therefore be avoided.
Grapefrugtjuice påvirker den CYP3A4- formidlede metabolisme og skal derfor undgås.
Grapefruit juice affects CYP3A4-mediated metabolism and must, therefore, be avoided.
Grapid 75 mg filmovertrukne tabletter clopidogrel
Grepid 75 mg film-coated tablets clopidogrel
Grastofil 30 ME/0,5 ml (0,6 mg/ml) injektions- og infusionsvæske, opløsning i en fyldt injektionssprøjte filgrastim
Grastofil 30 MU/0.5 mL (0.6 mg/mL) solution for injection or infusion in pre-filled syringe filgrastim
Grastofil 30 ME/0,5 ml injektions- og infusionsvæske, opløsning filgrastim
Grastofil 30 MU/0.5 mL solution for injection/infusion filgrastim
Grastofil 30 ME/0,5 ml injektions- og infusionsvæske, opløsning, i en fyldt injektionssprøjte
Grastofil 30 MU/0.5 mL solution for injection or infusion in pre-filled syringe
Grastofil 48 ME/0,5 ml (0,96 mg/ml) injektions- og infusionsvæske, opløsning i en fyldt injektionssprøjte filgrastim
Grastofil 48 MU/0.5 mL (0.96 mg/mL) solution for injection or infusion in pre-filled syringe filgrastim
Grastofil 48 ME/0,5 ml injektions- og infusionsvæske, opløsning filgrastim
Grastofil 48 MU/0.5 mL solution for injection/infusion filgrastim
Grastofil 48 ME/0,5 ml injektions- og infusionsvæske, opløsning, i en fyldt injektionssprøjte
Grastofil 48 MU/0.5 mL solution for injection or infusion in pre-filled syringe
Grastofil anvendes til at behandle børn, der får kemoterapi og lider af et svært nedsat antal hvide blodlegemer (neutropeni).
Grastofil is used to treat children who are receiving chemotherapy or who suffer from severe low white blood cell count (neutropenia).
Grastofil anvendes til at stimulere produktionen af hvide blodlegemer i følgende situationer:
Grastofil is used to stimulate the production of white blood cells in the following situations:
Grastofil blev anvendt i én hovedundersøgelse med deltagelse af 120 voksne kvindelige patienter med brystkræft, der blev behandlet med kræftmedicin (kemoterapi), som vides at medføre neutropeni.
Grastofil was studied in one main study involving 120 female adult patients with breast cancer treated with chemotherapy (medicines to treat cancer) known to cause neutropenia.
Grastofil burde ikke have nogen indvirkning på din evne til at føre motorkøretøj og betjene maskiner.
Grastofil should not affect your ability to drive and use machines.
Grastofil er et lægemiddel, der indeholder det aktive stof filgrastim.
Grastofil is a medicine that contains the active substance filgrastim.
Grastofil er ikke blevet undersøgt hos gravide eller ammende kvinder.
Grastofil has not been tested in pregnant or breast-feeding women.
Grastofil er indiceret til behandling af persisterende neutropeni (ANC mindre eller lig med 1,0 x 109/l) hos patienter med fremskreden hiv-infektion for at nedsætte risikoen for bakterielle infektioner, hvis der ikke er anden egnet behandling af neutropeni.
Grastofil is indicated for the treatment of persistent neutropenia (ANC less than or equal to 1.0 x 109/L) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.
Grastofil indeholder det aktive stof filgrastim.
Grastofil contains the active ingredient filgrastim.
Grastofil indeholder mindre end 1 mmol (0,035 mg) natrium pr. dosis, dvs. den er i det væsentlige natriumfri.
Grastofil also contains less than 1 mmol sodium (0.035 mg) per dose, i.e. essentially ‘sodium-free’.
Grastofil indeholder mindre end 1 mmol (0,035 mg) natrium pr. dosis, dvs. den er i det væsentlige natriumfri.
Grastofil contains less than 1 mmol sodium (0.035 mg) per dose, i.e. essentially ‘sodium-free’.
Grastofil indeholder sorbitol (E420) som et hjælpestof med en koncentration på 50 mg/ml.
Grastofil contains sorbitol (E420) as an excipient at a concentration of 50 mg/mL.
Grastofil indeholder sorbitol og natrium
Important information about some of the ingredients of Grastofil
Grastofil indeholder sorbitol.
Grastofil contains sorbitol.
Grastofil kan anvendes:
Grastofil can be used
Grastofil kan gives som en daglig subkutan injektion eller som en daglig intravenøs infusion efter fortynding med en 5 % glukose-opløsning over 30 minutter (se pkt.
Grastofil may be administered as a daily subcutaneous injection or as a daily intravenous infusion diluted in 5% glucose solution given over 30 minutes (see section 6.6).
Grastofil leveres som injektionsvæske i fyldte sprøjter eller som infusionsvæske (til drop).
Grastofil is available in pre-filled syringes as a solution for injection or infusion (drip).
Grastofil må ikke fortyndes med saltvandsopløsninger.
Grastofil must not be diluted with saline solutions.
Grastofil til PBPC-mobilisering efter myelosuppressiv kemoterapi: Grastofil skal gives som subkutan injektion.
Grastofil for PBPC mobilisation after myelosuppressive chemotherapy: Grastofil should be given by subcutaneous injection.
Grastofil til PBPC-mobilisering, når det anvendes alene:
Grastofil for PBPC mobilisation when used alone:
Grastofil tilhører en gruppe produkter, der stimulerer produktionen af hvide blodlegemer.
Grastofil is one of a group of products that stimulate the production of white blood cells.
Grastofils sikkerhed og virkning er den samme hos voksne og børn, der får cytotoksisk kemoterapi.
The safety and efficacy of Grastofil are similar in adults and children receiving cytotoxic chemotherapy.
Gravide blandt personalet må ikke håndtere lægemidlet.
Pregnant staff should be excluded from handling the medicinal product.
gravide eller ammende kvinder
pregnant or breast-feeding women;
gravide eller ammende kvinder
pregnant or breastfeeding women;
gravide eller ammende kvinder
women who are pregnant or breast-feeding
Gravide kaniner, der blev behandlet oralt med 7,5 mg/kg/dag (7500 gange den anbefalede oftalmiske dosis), forårsagede øget postimplantationstab (se pkt.
Pregnant rabbits treated orally with 7.5 mg/kg/day (7500 times the recommended ophthalmic dose) caused increased post- implantation loss (see section 4.6).
Gravide kvinder (se pkt.
Pregnant women (see section 4.6)
Gravide kvinder bland personalet, bør ikke arbejde med cytotoksiske medikamenter.
Pregnant staff should not handle the cytotoxic preparation.
Gravide kvinder blandt personalet må ikke arbejde med dette lægemiddel.
Pregnant staff should be excluded from working with this medicinal product.
Gravide kvinder blandt personalet, bør ikke arbejde med cytotoksiske medikamenter.
Pregnant staff should not handle the cytotoxic preparation.
Gravide kvinder bør ikke behandles med Raptiva
Pregnant women should not be treated with Raptiva.
Gravide kvinder bør ikke blive vaccineret med ProQuad
Pregnant women should not be vaccinated with ProQuad.
Gravide kvinder bør ikke indgive produktet.
Pregnant women should not administer the veterinary medicinal product.